Skip to content

Released May 10, 2024, before the open

10-Q filed May 10, 2024, 40 days after period end · 0001628280-24-022473

Q1 2024 · 10-Q
Revenue$591.00K— vs Q1 2023no prior Q4 2023 on file
Net Income-$45.76MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.44N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$48,341,000N/M
Operating Cash Flow-$67,707,000N/M
Free Cash Flowderived-$70,031,000N/M
Margins · derived
Operating margin-8179.5%
Net margin-7743.0%

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$591.00K$0.00——
Net Income-$45.76M-$39.40M-$23.84M-$86.66M
EPS Diluted-$0.44-$0.44-$1.58—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR